Synermore Biologics

News

2015/01 Synermore submitted IND Application of SYN004, an anti-colorectal cancer antibody drug to CFDA for Clinical Phase I trial Study

Synermore submitted IND Application of SYN004, an anti-colorectal cancer antibody drug to CFDA for Clinical Phase I trial Study

2013/11 Incorporated in November 15, 2013, Synermore Biologics Co. Ltd

Incorporated in November 15, 2013, Synermore Biologics Co. Ltd